Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian G Feagan

Showing results (311-320 of 464) with videos related to

Pageof 47
Sort By:
Gut|November 2, 2016
Disease activity indices in coeliac disease: systematic review and recommendations for clinical trialsPieter Hindryckx, Barrett G Levesque, Tom Holvoet, et al.
Journal of Crohn'S & Colitis|June 2, 2021
Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension StudyMarc Ferrante, Brian G Feagan, Julián Panés, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 20, 2020
Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative ColitisWilliam J Sandborn, Marc Ferrante, Bal R Bhandari, et al.
Inflammatory Bowel Diseases|November 1, 2011
Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus reportBrian G Feagan, Marc Lémann, Ragnar Befrits, et al.
Inflammatory Bowel Diseases|January 14, 2014
Histologic evaluation of ulcerative colitis: a systematic review of disease activity indicesMahmoud H Mosli, Brian G Feagan, William J Sandborn, et al.
Journal of Crohn'S & Colitis|March 20, 2023
A Phase 2b, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients with Moderately to Severely Active Crohn's DiseaseMatthieu Allez, Bruce E Sands, Brian G Feagan, et al.
Journal of Crohn'S & Colitis|June 4, 2019
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's DiseaseStephen B Hanauer, William J Sandborn, Brian G Feagan, et al.
The New England Journal of Medicine|June 17, 2005
Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrinBrian G Feagan, Gordon R Greenberg, Gary Wild, et al.
Alimentary Pharmacology & Therapeutics|August 1, 2024
Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension studyBrian G Feagan, Katsuyoshi Matsuoka, Gerhard Rogler, et al.
Alimentary Pharmacology & Therapeutics|September 3, 2020
Long-term safety of vedolizumab for inflammatory bowel diseaseEdward V Loftus, Brian G Feagan, Remo Panaccione, et al.
Pageof 47

Showing results (311-320 of 464) with videos related to

Sort By:
Pageof 47
Gut|November 2, 2016
Disease activity indices in coeliac disease: systematic review and recommendations for clinical trialsPieter Hindryckx, Barrett G Levesque, Tom Holvoet, et al.
Journal of Crohn'S & Colitis|June 2, 2021
Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension StudyMarc Ferrante, Brian G Feagan, Julián Panés, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 20, 2020
Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative ColitisWilliam J Sandborn, Marc Ferrante, Bal R Bhandari, et al.
Inflammatory Bowel Diseases|November 1, 2011
Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus reportBrian G Feagan, Marc Lémann, Ragnar Befrits, et al.
Inflammatory Bowel Diseases|January 14, 2014
Histologic evaluation of ulcerative colitis: a systematic review of disease activity indicesMahmoud H Mosli, Brian G Feagan, William J Sandborn, et al.
Journal of Crohn'S & Colitis|March 20, 2023
A Phase 2b, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients with Moderately to Severely Active Crohn's DiseaseMatthieu Allez, Bruce E Sands, Brian G Feagan, et al.
Journal of Crohn'S & Colitis|June 4, 2019
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's DiseaseStephen B Hanauer, William J Sandborn, Brian G Feagan, et al.
The New England Journal of Medicine|June 17, 2005
Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrinBrian G Feagan, Gordon R Greenberg, Gary Wild, et al.
Alimentary Pharmacology & Therapeutics|August 1, 2024
Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension studyBrian G Feagan, Katsuyoshi Matsuoka, Gerhard Rogler, et al.
Alimentary Pharmacology & Therapeutics|September 3, 2020
Long-term safety of vedolizumab for inflammatory bowel diseaseEdward V Loftus, Brian G Feagan, Remo Panaccione, et al.
Pageof 47